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Several tumor-derived factors have been implicated in
DC dysfunction in cancer patients. Alpha-fetoprotein
(AFP) is an oncofetal antigen that is highly expressed in
abnormalities of prenatal development and several
epithelial cancers, including hepatocellular carcinoma
(HCC). In HCC patients exhibiting high levels of serum
AFP, we have observed a lower ratio of myeloid-to-
plasmacytoid circulating DC compared to patients with
low serum AFP levels and healthy donors, suggesting
that AFP alters DC differentiation in vivo. To test the
effect of AFP on DC differentiation in vitro, peripheral
blood monocytes from healthy donors were cultured in
the presence of cord blood-derived normal AFP (nAFP)
or HCC tumor-derived AFP (tAFP), and DC phenotype
and function was assessed. Although the nAFP and
tAFP isoforms only differ at one carbohydrate group,
low (physiological) levels of tAFP, but not nAFP, signifi-
cantly inhibited DC differentiation. tAFP-conditioned
DC expressed diminished levels of DC maturation mar-
kers, retained a monocyte-like morphology, exhibited
limited production of inflammatory mediators, and
failed to induce robust T cell proliferative responses.
Mechanistic studies revealed that the suppressive activity
of tAFP is dependent on the presence of low molecular
weight (LMW) species that i) co-purify with tAFP, and ii)
are abundant in the LMW fractions of both tumor and
non-tumor cell lysates. These data reveal the unique ability
of tAFP to serve as a chaperone protein for ubiquitous
LMW molecules, which function cooperatively to impair
DC differentiation and function. Therefore, novel therapeu-
tic approaches that antagonize the regulatory properties of
tAFP will be critical to enhance immunity and improve
clinical outcomes.
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